GC
FENC icon

Globeflex Capital’s Fennec Pharmaceuticals FENC Stock Holding History

Globeflex Capital’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$113K Buy
+18,343
New +$142K 0.02% 355

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Globeflex Capital's FENC Position: Q1 2026 in Review

Globeflex Capital opened a new position in Fennec Pharmaceuticals (FENC) in Q1 2026: 18,343 shares worth $113K. The stake represents 0.02% of the portfolio and ranks #355 among its holdings.

90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Globeflex Capital held 18,343 shares of Fennec Pharmaceuticals worth $113K as of Q1 2026.
  • Fennec Pharmaceuticals was a new Globeflex Capital position in Q1 2026.
  • Fennec Pharmaceuticals made up 0.02% of Globeflex Capital's portfolio in Q1 2026, its #355 holding.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Globeflex Capital's 13F filing for Q1 2026, filed 13 May 2026.